Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Operating Expenses (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Operating Expenses for 16 consecutive years, with $27.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 6.3% to $27.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $110.6 million, a 12.15% increase, with the full-year FY2025 number at $110.6 million, up 12.15% from a year prior.
  • Operating Expenses was $27.4 million for Q4 2025 at Lemaitre Vascular, up from $25.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $28.8 million in Q2 2025 to a low of $15.7 million in Q2 2021.
  • A 5-year average of $22.1 million and a median of $22.8 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: dropped 1.71% in 2021, then surged 40.7% in 2022.
  • Lemaitre Vascular's Operating Expenses stood at $17.7 million in 2021, then grew by 8.11% to $19.1 million in 2022, then increased by 20.81% to $23.1 million in 2023, then increased by 11.61% to $25.7 million in 2024, then increased by 6.3% to $27.4 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Operating Expenses are $27.4 million (Q4 2025), $25.6 million (Q3 2025), and $28.8 million (Q2 2025).